New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 27, 2012
07:37 EDTSQNM, CI, AETNew guidelines on Sequenom test to be considered by insurers, WP says
New prenatal tests for genetic defects that require only a sample of the mother’s blood, as opposed to an invasive procedure, have come under scrutiny from major insurance companies for their high cost and limited data on accuracy and impact on care, reported The Washington Post. A new opinion from the The American College of Obstetricians and Gynecologists will be considered by insurers including Cigna (CI) and Aetna (AET) but is not considered "a clear endorsement” of the tests offered by Sequenom (SQNM) and others, according to the report. Reference Link
News For SQNM;CI;AET From The Last 14 Days
Check below for free stories on SQNM;CI;AET the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 31, 2014
14:00 EDTCIFBR Capital to hold a conference
Healthcare Conference to be held in Boston on September 3.
August 24, 2014
21:54 EDTSQNMPiper Jaffray to hold a bus tour
Subscribe for More Information
August 21, 2014
16:09 EDTCICigna expects to reaffirm FY14 income guidance of $1.94B-$2.0B
Subscribe for More Information
August 19, 2014
11:32 EDTSQNMLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use